296 related articles for article (PubMed ID: 32907837)
1. The Emerging Role of Ras Pathway Signaling in Pediatric Cancer.
Ney GM; McKay L; Koschmann C; Mody R; Li Q
Cancer Res; 2020 Dec; 80(23):5155-5163. PubMed ID: 32907837
[TBL] [Abstract][Full Text] [Related]
2. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
Chen Y; Takita J; Hiwatari M; Igarashi T; Hanada R; Kikuchi A; Hongo T; Taki T; Ogasawara M; Shimada A; Hayashi Y
Genes Chromosomes Cancer; 2006 Jun; 45(6):583-91. PubMed ID: 16518851
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Ras pathway in pediatric hematologic malignancies.
Pikman Y; Stieglitz E
Curr Opin Pediatr; 2021 Feb; 33(1):49-58. PubMed ID: 33394740
[TBL] [Abstract][Full Text] [Related]
4. Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.
Gross AM; Frone M; Gripp KW; Gelb BD; Schoyer L; Schill L; Stronach B; Biesecker LG; Esposito D; Hernandez ER; Legius E; Loh ML; Martin S; Morrison DK; Rauen KA; Wolters PL; Zand D; McCormick F; Savage SA; Stewart DR; Widemann BC; Yohe ME
Am J Med Genet A; 2020 Apr; 182(4):866-876. PubMed ID: 31913576
[TBL] [Abstract][Full Text] [Related]
5. Past, Present, and Future Therapeutic Strategies for NF-1-Associated Tumors.
Na B; Shah SR; Vasudevan HN
Curr Oncol Rep; 2024 Jun; 26(6):706-713. PubMed ID: 38709422
[TBL] [Abstract][Full Text] [Related]
6. RASopathies: From germline mutations to somatic and multigenic diseases.
Riller Q; Rieux-Laucat F
Biomed J; 2021 Aug; 44(4):422-432. PubMed ID: 34175492
[TBL] [Abstract][Full Text] [Related]
7. Targeting oncogenic Ras signaling in hematologic malignancies.
Ward AF; Braun BS; Shannon KM
Blood; 2012 Oct; 120(17):3397-406. PubMed ID: 22898602
[TBL] [Abstract][Full Text] [Related]
8. K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2017 Jan; 125():299-314. PubMed ID: 27688185
[TBL] [Abstract][Full Text] [Related]
9. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
10. Biology, pathology, and therapeutic targeting of RAS.
Rhett JM; Khan I; O'Bryan JP
Adv Cancer Res; 2020; 148():69-146. PubMed ID: 32723567
[TBL] [Abstract][Full Text] [Related]
11. RAS diseases in children.
Niemeyer CM
Haematologica; 2014 Nov; 99(11):1653-62. PubMed ID: 25420281
[TBL] [Abstract][Full Text] [Related]
12. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibitors in RASopathies.
Bergqvist C; Wolkenstein P
Curr Opin Oncol; 2021 Mar; 33(2):110-119. PubMed ID: 33395032
[TBL] [Abstract][Full Text] [Related]
14. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A; Nebozhyn M; Klinghoffer R; Frazier J; Chastain M; Arthur W; Roberts B; Zhang T; Chenard M; Haines B; Andersen J; Nagashima K; Paweletz C; Lynch B; Feldman I; Dai H; Huang P; Watters J
BMC Med Genomics; 2010 Jun; 3():26. PubMed ID: 20591134
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications.
Imperial R; Toor OM; Hussain A; Subramanian J; Masood A
Semin Cancer Biol; 2019 Feb; 54():14-28. PubMed ID: 29175106
[TBL] [Abstract][Full Text] [Related]
16. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
[TBL] [Abstract][Full Text] [Related]
17. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
Jerchel IS; Hoogkamer AQ; Ariës IM; Steeghs EMP; Boer JM; Besselink NJM; Boeree A; van de Ven C; de Groot-Kruseman HA; de Haas V; Horstmann MA; Escherich G; Zwaan CM; Cuppen E; Koudijs MJ; Pieters R; den Boer ML
Leukemia; 2018 Apr; 32(4):931-940. PubMed ID: 28972594
[TBL] [Abstract][Full Text] [Related]
18. Understanding and drugging RAS: 40 years to break the tip of the iceberg.
Brady DC; Hmeljak J; Dar AC
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35244677
[TBL] [Abstract][Full Text] [Related]
19. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
Rauen KA; Schoyer L; Schill L; Stronach B; Albeck J; Andresen BS; Cavé H; Ellis M; Fruchtman SM; Gelb BD; Gibson CC; Gripp K; Hefner E; Huang WYC; Itkin M; Kerr B; Linardic CM; McMahon M; Oberlander B; Perlstein E; Ratner N; Rogers L; Schenck A; Shankar S; Shvartsman S; Stevenson DA; Stites EC; Stork PJS; Sun C; Therrien M; Ullian EM; Widemann BC; Yeh E; Zampino G; Zenker M; Timmer W; McCormick F
Am J Med Genet A; 2018 Dec; 176(12):2924-2929. PubMed ID: 30302932
[TBL] [Abstract][Full Text] [Related]
20. Targeting RAS signalling pathways in cancer therapy.
Downward J
Nat Rev Cancer; 2003 Jan; 3(1):11-22. PubMed ID: 12509763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
